The transcription factor E2F1 controls the GLP-1 receptor pathway in pancreatic β cells.
Cell Rep · 2022
Last updated 2026-05-28A study found that a protein called E2F1 helps control how well pancreatic beta cells respond to GLP-1, a hormone that improves blood sugar control in type 2 diabetes. When E2F1 was removed from beta cells in mice, the cells made less of the GLP-1 receptor and had worse blood sugar control. In human beta cells, blocking E2F1 reduced GLP-1 receptor levels and weakened the effect of a GLP-1 drug (exendin-4) on insulin release. Increasing E2F1 boosted GLP-1 receptor levels and strengthened the drug's effect on insulin.
AI summary of the abstract below.
| Journal | Cell Rep, 2022 |
|---|---|
| Citations | 13 |
| Relative citation ratio | 1.14 |
| NIH percentile | 55 |
| Molecules | — |
| Conditions studied | Type 2 Diabetes |
Abstract
The glucagon-like peptide 1 (Glp-1) has emerged as a hormone with broad pharmacological potential in type 2 diabetes (T2D) treatment, notably by improving β cell functions. The cell-cycle regulator and transcription factor E2f1 is involved in glucose homeostasis by modulating β cell mass and function. Here, we report that β cell-specific genetic ablation of E2f1 (E2f1) impairs glucose homeostasis associated with decreased expression of the Glp-1 receptor (Glp1r) in E2f1 pancreatic islets. Pharmacological inhibition of E2F1 transcriptional activity in nondiabetic human islets decreases GLP1R levels and blunts the incretin effect of GLP1R agonist exendin-4 (ex-4) on insulin secretion. Overexpressing E2f1 in pancreatic β cells increases Glp1r expression associated with enhanced insulin secretion mediated by ex-4. Interestingly, ex-4 induces retinoblastoma protein (pRb) phosphorylation and E2f1 transcriptional activity. Our findings reveal critical roles for E2f1 in β cell function and suggest molecular crosstalk between the E2F1/pRb and GLP1R signaling pathways.
Verbatim abstract via PubMed 35947949 ↗